Gudrun Würthwein, Oliver A Cornely, Mirjam N Trame, Janne J Vehreschild, Maria J G T Vehreschild, Fedja Farowski, Carsten Müller, Joachim Boos, Georg Hempel, Michael Hallek, Andreas H Groll
Caspofungin (CAS) is approved for second-line management of proven or probable invasive aspergillosis at a dose of 50 mg once daily (QD). Preclinical and limited clinical data support the concept of the dose-dependent antifungal efficacy of CAS with preservation of its favorable safety profile. Little is known, however, about the pharmacokinetics (PKs) of higher doses of CAS in patients. In a formal multicenter phase II dose-escalation study, CAS was administered as a 2-h infusion at doses ranging from 70 to 200 mg QD...
April 2013: Antimicrobial Agents and Chemotherapy